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ABSTRACT
Objectives: Gestational diabetes mellitus (GDM) is a metabolic disease diagnosed in 1.7% up to 11.6% pregnancies. The 
prevalence of adverse pregnancy outcome is significantly higher in the case of early onset of diabetes mellitus. Adropin is 
a hormone promoting carbohydrate oxidation over fat oxidation, and influence nitric oxide synthase. Copeptin is a cleav-
age product of the vasopressin precursor recently correlated with diabetes mellitus. The aim of the study was to determine 
maternal serum adropin and copeptin concentrations in women with early and late manifestation of GDM and to discuss 
their potential role as biochemical markers of insulin resistance.
Material and methods: Case-control study on 58 pregnant Caucasian women. Serum levels of adropin and copeptin were 
assessed in patients with early onset (GDM1) and classical gestational diabetes mellitus (GDM2). Complications such as 
macrosomia and hypotrophy were evaluated.
Results: There was no significant difference between the study and the control group (age, BMI, parity). Fetal growth 
disturbance rate was 37.5% in GDM1, 11% in GDM2 and 6% in controls. Adropin concentration in GDM patients was 
significantly higher than in control group (p < 0.001), but there was no difference between GDM1 and GDM2 group. High 
serum concentration of adropin positively correlated with elevated HbA1c (p < 0.05). The groups did not differ in terms of 
copeptin serum concentration.
Conclusions: High adropin serum concentration in GDM patients is associated with increased risk of fetal growth distur-
bances, possibly due to improper placentation. According to our prospective study, neither copeptin nor adropin serum 
concentration are useful to discriminate between early and late onset of gestational diabetes mellitus.
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INTRODUCTION
Gestational diabetes mellitus (GDM) is a metabolic dis-
ease defined as hyperglycemia with blood glucose values 
above normal, but below those diagnostic for diabetes, 
with its onset or being first diagnosed during pregnancy. 
The prevalence of GDM varies between populations, rang-
ing from 1.7% to 11.6% [1]. Numerous studies found that 
GDM is associated with significantly higher maternal (ce-
sarean section, gestational hypertension, preeclampsia), 
perinatal (macrosomia and birth injury) and postnatal (early 
onset of metabolic syndrome, diabetes and hypertension in 
children) complications risk [2, 3]. The prevalence of adverse 
pregnancy outcome is significantly higher in the case of 
early onset of diabetes mellitus. 
Throughout pregnancy, maternal glucose metabolism 
undergoes multiple, adaptive changes to ensure adequate 
fetal development. In conditions of increased glucose utili-
zation by feto-placental unit and high level of human pla-
cental lactogen, placenta-derived human growth factor 
hormone, progesterone, cortisol, prolactin and many other 
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hormones, decreasing insulin sensitivity occurs in peripheral 
tissues [4]. As a compensation, both maternal hepatic gluco-
neogenesis and fatty acid levels increase [5]. Accompanied 
by certain environmental and genetic factors, maternal 
metabolism is not able to properly compensate increasing 
insulin resistance and together with the impaired insulin 
secretion and higher level of hepatic gluconeogenesis result 
in elevated glycaemia [6]. 
Adropin (ADR) is a 42-amino-acid peptide hormone that 
participates in maintaining glucose homeostasis. Recently, 
a novel role for ADR was reported in promoting carbohy-
drate oxidation over fat oxidation in skeletal muscles [7]. 
Moreover, adropine’s influence on expression of an inducible 
nitric oxide synthase was discovered [8], which can explain 
ADRs’ potential role in prediction of endothelial dysfunction 
in patients with diabetes mellitus [9]. 
Several reports suggest that stress-mediated activation 
of the HPA axis, accompanied by increased plasma levels of 
arginine vasopressin (AVP) may play a crucial role in patho-
genesis of insulin resistance and metabolic syndrome [10]. 
AVP binds with three different receptors: V1aR, V1bR and 
V2R. Activation of V1aR in hepatocytes increases glycog-
enolysis, whereas binding with V1bR in pituitary gland and 
pancreas lead to insulin and glucagon secretion [11, 12]. 
Copeptin is a cleavage product of the C-terminal part of the 
AVP precursor, stable and with long half-life, which is also 
known as a surrogate hormone for AVP. In recent studies, 
the correlation with elevated plasma copeptin and diabetes 
mellitus has been investigated [13].
Although there are many similarities between early and 
late onset of diabetes, in both cases the underlying patho-
physiology remains unclear. For many decades, a lot of effort 
has been made to find biochemical markers, which would 
improve screening for GDM, with no satisfactory result.
OBJECTIVES
To the best of our knowledge, this is one of very few 
studies that investigate adropin and copeptin serum con-
centration in women with early and late onset of GDM. The 
aim of this study was to investigate whether maternal serum 
adropin and copeptin concentrations are altered in women 
with early and late manifestation of GDM and to discuss their 
potential role as biochemical markers of insulin resistance.
MATERIAL AND METHODS
This case-control study was performed from July 
2014 until August 2015 in 1st Department of Obstetrics 
and Gynecology, Medical University of Warsaw. An informed 
consent was obtained from all patients on forms approved 
by the Ethics Committee of Medical University of Warsaw. 
Fifty eight Caucasian women were recruited, 20 with GDM 
diagnosed in the 1st trimester (GDM1 group), 20 with clas-
sical GDM (GDM2 group) and 18 controls (noGDM1 and 
noGDM2 group) with uncomplicated pregnancies. Blood 
samples were collected in the 1st (GDM1 and noGDM1 group) 
and 3rd trimester (GDM2 and noGDM2) for examinations in 
Department of Experimental and Clinical Physiology, Medi-
cal University of Warsaw. All patients gave written informed 
consent before the study began.
GDM was defined as fasting glucose > 5.11 mmol/L 
and/or OGTT results 0 h > 5.11, 1h > 10, 2 h > 8.5 mmol/L. 
All GDM patients received education in carbohydrates 
restriction diet, exercise and glycaemia monitoring. They 
kept a journal of food intake and glycaemia levels (4 to 
9 point). Thanks to careful diet, blood glucose levels were 
within normal range (fasting < 5.28 mmol/L, postprandi-
al < 7.22 mmol/L) and none of them needed insulin treat-
ment. Except for GDM status, pregnancy complications such 
as cesarean section, macrosomia, and hypotrophy were 
evaluated. 
Exclusion criteria were as follows: preeclampsia, a his-
tory of fetal anomalies, chronic diseases (e.g. AIDS, hepatitis, 
renal insufficiency, and heart disease), premature rupture 
of membranes prior to 24th week, intrauterinal infection. 
Gestational age was estimated by the last menstrual period 
and was confirmed by 1st trimester ultrasound. Women 
from the control group had no significant medical history, 
no pregnancy-related complications and no risk factors for 
gestational diabetes. 1st trimester fasting glucose and a 75 g 
3-point glucose tolerance test in 3rd trimester values were 
within normal range. 
At the time of GDM diagnosis, serum samples were 
collected from pregnant women. All samples were kept at 
room temperature for at least 60 min to allow the blood 
clot formation and were later centrifuged at 20 000 RPM 
for 5 min and kept frozen in –80° Celsius. Serum copeptin 
concentrations were measured by enzyme immunoassay 
(EIA) using the following commercially available reagent 
kits: Copeptin (Human) — EIA Kit; kit Extraction free, Phoe-
nix Pharmaceuticals, INC; Minimum Detectable Concentra-
tion = 0.12 ng/mL. Serum adropin concentrations were 
measured by enzyme-linked immunosorbent assay (ELISA) 
using the following commercially available reagent kits: Hu-
man (AD) ELISA Kit, Sunred Biological Technology Co., Shang-
hai, Minimum Detectable Concentration = 0.306 ng/mL.
All statistical analyses were performed using the Graph-
Pad, MS Office Excel 2010 and Statistica 10 software. Data 
were presented as mean ± standard deviation. Mean values 
between the groups were compared by Student’s T-test. 
Pearson’s correlation coefficient was used to determine the 
relationship between the variables. Power of the statisti-
cal test, which the compared groups were analysed with, 
ranged from 0.739 to 0.996. In the calculation of power of the 
test as a criterion of the quantity, minimum n in the groups 
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has been assumed. All reported p values are two-tailed and 
a p < 0.05 was considered significant.
RESULTS
There was no statistical difference between the study 
and the control patients in terms of age, blood pressure, 
gestational age at delivery and weight gain (Tab. 1). Patients 
who developed GDM were significantly more overweight 
before pregnancy. In GDM1, body mass index (BMI) was 
26.33 ± 6.42, and in GDM2 28.26 ± 5.99, while in controls 
— 22.9 ± 4.1 kg/m2 ( p < 0.001).
Comparison of BMI between GDM1, GDM2 and con-
trol groups are described in Figure 1 and comparison 
of serum concentration of fasting glucose, adropin and 
copeptin between GDM1 and GDM2 groups are de-
scribed in Figure 2. Figure 3 presents differences in dis-
tribution of those characteristics between controls and 
diabetic patients. Adropin concentration in GDM patients 
(11.78 ± 1.09 ng/ml) was significantly higher than in con-
trol group (5.68 ± 1.27 ng/mL, p < 0.001), but there was 
no difference between GDM1 (12.71 ± 1.79 ng/mL) and 
GDM2 (11.12 ± 1.39 ng/mL) group.
We did not find statistically important differences be-
tween GDM patients versus controls in neonatal weight at 
delivery (42.9 pc in GDM1 ± 33.9, 52.1 pc ± 26.1 in GDM2, and 
41.2 pc ± 24.7 in controls). Interestingly, the cesarean section 
rate was higher in control group (p < 0.05).
Although the difference in neonatal weight was not 
statistically significant, it is worth to note that there were 
6 cases (37.5 %) in GDM1 group of growth disturbances 
(3 hypotrophic 10 pc, and 3 macrosomic > 90 pc) vs. only 
2 macrosomic neonates in GDM2 (11%) and only 1 hypo- 
trophic child in no GDM patients (6 %). 
Adropin serum concentration in diabetic patients was 
significantly higher than in control group (p > 0.001), but 
there was no difference in copeptin serum concentration 
(Tab. 2).
Analysis of correlation found no link between adropin 
and copeptin serum concentration and fasting glucose or 
BMI. We found a significant correlation between high serum 
concentration of adropin and elevated HbA1c (p < 0.05), 
suggesting long lasting disease and possible carbohydrate 
disturbances prior to pregnancy. 
DISCUSSION
The key finding of our study is that maternal serum adro-
pin in women with GDM, both diagnosed in the first and third 
trimester, is significantly elevated in respect to non-diabetic 
Table 1. Characteristics of the patients
Characteristic GDM1 GDM2 Control
BMI before pregnancy [kg/m2] 28.20 ± 7.78 24.45 ± 4.10 22.90 ± 4.10
BMI before delivery [kg/m2] 28.41 ± 7.55 28.09 ± 4.07 27.20 ± 4.66
Fasting glucose 1st trimester [mmol/L] 5.50 ± 0.65 4.95 ± 0.31 4.37 ± 0.37
% tile at delivery [no.] 42.88 ± 33.93 52.06 ± 26.10 41.20 ± 24.68
BMI — body mass index; GDM1 — gestational diabetes mellitus diagnosed in the 1st trimester; GDM2 — gestational diabetes mellitus diagnosed in the 3rd trimester
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Figure 1. Body mass index (BMI) in patients with gestational diabetes mellitus diagnosed in the 1st (GDM1) and 3rd (GDM2) trimester and control 
groups (no GDM1, no GDM2) before and during pregnancy
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Figure 3. Serum concentration of fasting glucose, adropin and copeptin in diabetic patients (pooled group GDM1+2) and control group
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Figure 2. Serum concentration of fasting glucose, adropin and copeptin in patients with gestational diabetes mellitus diagnosed in the 1st (GDM1) 
and 3rd (GDM2) trimester
pregnant women. Adropin is encoded by the Energy Ho-
meostasis Associated (Enho) gene that is widely expressed 
in the central nervous system, as well as peripheral tissues 
such as liver, the heart and skeletal muscles [14–16]. While 
the mechanism of release remains controversial, the rapid 
regulation according to energy and nutritional status has 
been observed. Gao Su et al. (2015) in their study on obese 
mice with insulin resistance suggest the therapeutic effects 
of adropin on glucose tolerance. They concluded that adropin 
improves glucose clearance, ameliorates insulin resistance 
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and reverses dyslipidemia. Moreover, increased release of 
adropin is related to the fed state and increased glucose 
oxidation by pyruvate dehydrogenase (PDH) complex activa-
tion. Furthermore, adropin inhibits carnitine palmitoyltrans-
ferase-1B (CPT1B), which reduces fatty acid oxidation (FAO) in 
muscles [17]. According to recent studies, it can be speculated 
that higher concentration of adropin in women with GDM is 
one of the multiple adaptive responses on adverse glucose 
metabolism during pregnancy. The use of adropin as a bio-
chemical marker for insulin resistance can be considered. In 
the study of Topuz et al., adropin and hemoglobin A1c were 
deemed independent risk factors for endothelial dysfunction 
in individuals with type 2 diabetes mellitus [9]. In pregnancy, 
endothelial dysfunction can contribute to the impaired pla-
centation in the 1st trimester and higher prevalence of late 
gestational complications such as preeclampsia, fetal growth 
disturbance, placental abruption or intrauterine fetal death. In 
our study group, the rate of pregnancy complications related 
with placentation disturbance did not reach statistically sig-
nificant superiority. To investigate the influence of maternal 
adropin concentration on placentation in early pregnancy 
further studies are required. 
In the recent literature, also mainly discussed is an in-
creased concentration of serum copeptin in pregnant women 
in relation to preeclampsia or fetal growth restrictions [18]. 
According to one of the few studies on pregnant women 
with GDM, a significant correlation between copeptin and 
HOMA-IR was found [19]. An association between elevated 
copeptin and increased risk of type 2 diabetes mellitus later 
in file was observed [20]. In the population-based study 
conducted in Sweden, copeptin was an independent pre-
dicting factor for diabetes mellitus [21]. In an animal study, 
elevated AVP level as a result of AVP resistance at the level of 
V1aR was related to insulin resistance and diabetes mellitus 
[22, 23]. However, a recent study of Yeung and coauthors 
(2014) investigates serum copeptin levels during pregnancy 
in relation to multiple pregnancy complications risk. There, 
in one of the largest reports, association between increased 
copeptin concentration and occurrence of preeclampsia 
were confirmed and no correlation to gestational diabetes 
was found [24]. Likewise in our study, an elevated serum 
concentration of copeptin in GDM patients, both in the first 
and in the third trimester, was not statistically significant. In 
conclusion, although copeptin seems to play an important 
role in AVP system and can be useful in screening for preec-
lampsia, its role as a marker for insulin resistance and GDM 
remains questionable. However, it should be noted that our 
study had limitation. The sample size for GDM patients was 
relatively small.
Adropin and copeptin affect glucose homeostasis. Avail-
able literature reports few discrepant results concerning 
adropin and copeptin blood concentration in women with 
gestational diabetes mellitus. Although the levels in those 
pregnant patients are affected by GDM change, their in-
fluence on insulin resistance in pregnancy needs further 
investigation. 
CONCLUSIONS
High adropin serum concentration in GDM patients is 
associated with increased risk of fetal growth disturbances, 
possibly due to improper placentation. According to our 
prospective study, neither copeptin nor adropin serum con-
centration are useful to discriminate between early and late 
onset of gestational diabetes mellitus.
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